Genmab A (GMAB) Change in Intangibles (2023 - 2025)
Genmab A's (GMAB) quarterly Change in Intangibles came in at -$18.0 million in Q3 2025, down 800.0% on a YoY basis from $2.6 million in Q3 2024, and little changed quarter-over-quarter from -$18.0 million in Q2 2025.
Analysis
Genmab A (GMAB) Change in Intangibles (2023 - 2025) Analysis & Trends
Genmab A (GMAB) has reported Change in Intangibles for 3 consecutive years, with -$18.0 million the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Change in Intangibles fell 800.0% year-over-year to -$18.0 million; the trailing twelve-month figure through Sep 2025 stood at -$71.0 million (down 2266.67% YoY), and the FY2025 full-year result was -$18.0 million, down 5.88% from the prior year.
- Change in Intangibles steadied at -$18.0 million in Q3 2025 per GMAB's latest filing, from -$18.0 million in the prior quarter.
- Across five years, Change in Intangibles topped out at -$1.0 million in Q4 2023 and bottomed at -$18.0 million in Q1 2025.
- Historically, Change in Intangibles has averaged -$12.3 million across 3 years, with a median of -$17.5 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Change in Intangibles sank 1600.0% in 2024, then sank 800.0% in 2025.
- Over 3 years, Change in Intangibles stood at -$1.0 million in 2023, then tumbled by 1600.0% to -$17.0 million in 2024, then declined by 5.88% to -$18.0 million in 2025.
- According to Business Quant data, Change in Intangibles over the past three periods registered -$18.0 million, -$18.0 million, and -$18.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -18.00 Mn |
| Jun 30, 2025 | -18.00 Mn |
| Mar 31, 2025 | -18.00 Mn |
| Dec 31, 2024 | -17.00 Mn |
| Sep 30, 2024 | -2.00 Mn |
| Dec 31, 2023 | -1.00 Mn |